The Myklebost group arranged a succesful workshop for the EU "Network of Excellence on Bone Tumours", Research Line 2: "Osteogenic tumours and related sarcomas", in which they are Work Package Leaders. Thirty participants from ten European countries - including several clinicians from the National Competence Centre for Sarcomas - discussed progress and plans during a two-day meeting held June 10-12th at Lysebu Conference Centre.
Bjørnerud B, Wesche J, Haugsten EM(2025) A rhabdomyosarcoma cell migration inhibitor screen using phase-contrast microscopy Exp Cell Res, 114582(in press) DOI 10.1016/j.yexcr.2025.114582, PubMed 40320199
Yip D, Zalcberg J, Blay JY, Eriksson M, Espinoza D, Price T, Marreaud S, Italiano A, Steeghs N, Boye K, Underhill C, Gebski V, Simes J, Gelderblom H, Joensuu H(2025) Imatinib alternating with regorafenib compared to imatinib alone for the first-line treatment of advanced gastrointestinal stromal tumor: The AGITG ALT-GIST intergroup randomized phase II trial Br J Cancer(in press) DOI 10.1038/s41416-025-02983-w, PubMed 40133509
Naolou T, Schadzek N, Hornbostel JM, Pepelanova I, Frommer M, Lötz F, Sauheitl L, Dultz S, Felde VJMNL, Myklebost O, Lee-Thedieck C(2025) Enhanced gelatin methacryloyl nanohydroxyapatite hydrogel for high-fidelity 3D printing of bone tissue engineering scaffolds Biofabrication, 17(2) DOI 10.1088/1758-5090/adbb90, PubMed 40020249